Preparation of manganese-doped layered double hydroxide drug-loaded nanoparticles and application of manganese-doped layered double hydroxide drug-loaded nanoparticles in tumor phototherapy and immune combined therapy

By preparing manganese-doped layered double hydroxide drug-loaded nanoparticles, combined with near-infrared laser irradiation, the problem of poor effect of phototherapy in deep or metastatic tumor treatment is solved, and more efficient tumor killing and immunity are achieved Activation significantly improves the therapeutic effect.

CN118903459APending Publication Date: 2024-11-08INST OF BIOMEDICAL ENG CHINESE ACAD OF MEDICAL SCI

Patent Information

Application Number
CN202410996870.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-24
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing phototherapy is not effective in treating deep or metastatic tumors, and the nonspecific distribution of phototherapeutic agents leads to low efficacy and cannot completely prevent tumor recurrence and metastasis.

Method used

Manganese-doped layered double hydroxide drug-loaded nanoparticles were prepared, and photosensitizer was loaded into the nanostructure to improve light stability, and the STING pathway was activated using manganese elements, combined with near-infrared laser irradiation to enhance the tumor killing effect.

Benefits of technology

It improves the effect of photothermal therapy, enhances the killing ability of tumor cells, relieves hypoxia microenvironment, promotes activation of immune cells, and significantly improves the efficacy and safety of tumor treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903459A_ABST
    Figure CN118903459A_ABST
Patent Text Reader

Abstract

The invention relates to the field of tumor drug delivery and combined therapy, in particular to preparation of manganese-doped layered double hydroxide drug-loaded nanoparticles and application of the manganese-doped layered double hydroxide drug-loaded nanoparticles in tumor phototherapy and immune combined therapy. According to the preparation method, a basic structure of an LDH nanosheet is firstly synthesized, then manganese element is simply doped into a laminated structure of the nanosheet through isomorphic substitution / doping of metal elements, and finally the manganese-doped layered double hydroxide drug-loaded nanoparticles are prepared, and the nanoparticles have good biocompatibility and degradability. The compound has good phototherapy performance, the photostability of the compound is further improved by loading the photosensitizer in the sheet nanostructure of the MLDH, and the photobleaching characteristic is effectively avoided, so that the photothermal effect is improved; in addition, manganese doped in the compound can effectively activate an STING pathway, relieve a hypoxic microenvironment and further improve the effect of photodynamic therapy, and tumors can be effectively killed in combination with near-infrared laser irradiation.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of tumor drug delivery and combined therapy, and in particular to the preparation of manganese-doped layered double hydroxide drug-loaded nanoparticles and their application in tumor phototherapy and immunotherapy combined therapy. Background Art

[0002] Layered double hydroxide (LDH) nanomaterials are two-dimensional nanomaterials with multilayer structures and possess a variety of excellent physical and chemical properties. Due to their unique structural composition, LDHs can provide a considerable specific surface area, giving them a high drug loading capacity and biological activity. In addition to their excellent drug loading performance, due to the positive charge of the layers, LDHs can be used as a "molecular switch" to respond to the tumor microenvironment and intelligently release drugs, reduce drug side effects, and enhance tumor killing effects. They are widely used in the field of tumor treatment.

[0003] Phototherapy is mainly divided into photothermal therapy (PTT) and photodynamic therapy (PDT). Phototherapy agents (such as photosensitizers, photothermal converters, etc.) are used to kill tumors by generating high heat and reactive oxygen species under the irradiation of specific light sources, which is considered to be a promising cancer treatment method. Compared with traditional treatment methods such as surgical resection, chemotherapy, and radiotherapy, phototherapy has unique advantages such as minimally invasiveness, high compliance, and relative clinical safety due to its light source's strong tissue penetration depth, strong specificity, and no obvious toxic side effects on normal tissues. However, due to the limited tissue penetration depth of commonly used light sources, traditional phototherapy is limited to superficial tumors and cannot completely prevent tumor recurrence and metastasis. In addition, the nonspecific distribution of phototherapy agents is also one of the important factors leading to the low efficacy of phototherapy. The development of multifunctional phototherapy agents and the combination of phototherapy with other treatment methods can effectively circumvent the existing limitations of phototherapy and enhance the therapeutic effect of tumors.

[0004] The present invention intends to improve the effect of photodynamic therapy by preparing a manganese-doped layered double hydroxide drug-loaded nanoparticle, and combine it with near-infrared laser irradiation to achieve the purpose of effectively killing tumor cells. At present, there is no literature or patent report on synthesizing nanosheets first, then simply incorporating manganese elements into the layer structure of nanosheets by hydrothermal reaction, preparing manganese-doped layered double hydroxide drug-loaded nanoparticles, and combining it with near-infrared laser irradiation to treat cancer. Summary of the invention

[0005] The purpose of the present invention is to provide a preparation method of manganese-doped layered double hydroxide drug-loaded nanoparticles and its application in tumor phototherapy and immunotherapy combined treatment to solve the problems existing in the above-mentioned prior art. The present invention provides a method for preparing manganese-doped layered double hydroxide drug-loaded nanoparticles. The prepared manganese-doped layered double hydroxide drug-loaded nanoparticles have good phototherapy performance. By loading the photosensitizer into the sheet nanostructure of MLDH, its photostability is further improved, and the photobleaching characteristics are effectively avoided, thereby improving the photothermal effect; in addition, the manganese doped in the complex can effectively activate the STING pathway, alleviate the hypoxic microenvironment, further improve the effect of photodynamic therapy, and can effectively kill tumors in combination with near-infrared laser irradiation.

[0006] To achieve the above object, the present invention provides the following solutions:

[0007] The present invention provides a method for preparing manganese-doped layered double hydroxide drug-loaded nanoparticles, comprising the following steps:

[0008] (1) After fully mixing the MgCl2 solution and the AlCl3 solution, the mixture is added to the NaOH solution to obtain a mixed solution;

[0009] (2) centrifuging the mixed solution and collecting the precipitate to obtain a precipitate;

[0010] (3) resuspending the precipitate in deionized water, and sequentially performing hydrothermal treatment and centrifugation to obtain LDH precipitate;

[0011] (4) resuspending the LDH precipitate with a MnCl2 solution, stirring and centrifuging in sequence to obtain a centrifugal precipitate;

[0012] (5) resuspending the centrifugal precipitate with deionized water, and then performing hydrothermal treatment and centrifugation in sequence to obtain a manganese-doped LDH precipitate;

[0013] (6) After freeze-drying the manganese-doped LDH precipitate, mixing it with a photosensitizer, and performing shaking treatment and centrifugation to obtain the manganese-doped layered double hydroxide drug-loaded nanoparticles.

[0014] Preferably, in step (1), the MgCl2 solution is an anhydrous MgCl2 solution; the AlCl3 solution is an AlCl3·6H2O solution;

[0015] The concentration ratio of the MgCl2 solution, the AlCl3 solution and the NaOH solution is (1-1.4)M:(0.5-1)M:(0.45-1)M;

[0016] The volume ratio of the MgCl2 solution, the AlCl3 solution and the NaOH solution is 5:5:40.

[0017] Preferably, in step (2), the centrifugal treatment condition parameters are (4300-5000) g centrifugation for 10 min.

[0018] Preferably, in step (3), the temperature of the hydrothermal treatment is (90-120)°C and the time is 4 hours; the centrifugal condition parameters are (12000-15000) g for 10 minutes.

[0019] Preferably, in step (5), the temperature of the hydrothermal treatment is (90-120)°C and the time is 4 hours; the centrifugal condition parameters are (12000-15000) g for 10 minutes.

[0020] Preferably, in step (6), the mass ratio of the lyophilized powder obtained after lyophilization to the photosensitizer is (0.05-0.1):1.

[0021] Preferably, the photosensitizer is one of indocyanine green, IR780 and IR820.

[0022] The invention provides manganese-doped layered double hydroxide drug-carrying nanoparticles prepared by the preparation method.

[0023] The present invention provides the use of the above-mentioned manganese-doped layered double hydroxide drug-carrying nanoparticles in the preparation of anti-tumor drugs.

[0024] The present invention provides an anti-tumor system, which comprises: a) the above-mentioned manganese-doped layered double hydroxide drug-loaded nanoparticles; and b) a light irradiation device.

[0025] The present invention discloses the following technical effects:

[0026] (1) The present invention first synthesizes the basic structure of LDH nanosheets, and then simply incorporates manganese elements into the layer structure of the nanosheets through isomorphic substitution / doping of metal elements, and finally prepares manganese-doped layered double hydroxide drug-loaded nanoparticles. Manganese-doped layered double hydroxide drug-loaded nanoparticles have good biocompatibility and degradability, and can effectively load photosensitizers while effectively doping manganese elements. Compared with directly achieving metal isomorphic substitution in the process of synthesizing nanosheets through hydrothermal reaction, the method of first synthesizing nanosheets and then performing isomorphic substitution of metal elements described in the present invention has many advantages, including the ability to accurately control the metal isomorphic substitution position, improve the stability and uniformity of nanosheets, reduce the influence of reaction conditions on the structure of nanosheets, and expand the scope of application.

[0027] (2) The manganese-doped layered double hydroxide drug-loaded nanoparticles prepared by the present invention have good phototherapy properties, can effectively avoid the photobleaching characteristics of photosensitizers, can generate higher heat under low-power near-infrared light irradiation, and can effectively kill tumor cells.

[0028] (3) The manganese-doped layered double hydroxide drug-loaded nanoparticles prepared by the present invention have good water solubility. After intratumoral injection, they can disintegrate under the weak acidic factors of the tumor microenvironment, neutralize the acidic microenvironment, and relieve immunosuppression. On the one hand, the doped manganese element catalyzes H2O2 to produce O2, alleviates the tumor hypoxic microenvironment, improves the effect of photodynamic therapy, and is conducive to promoting the activation and infiltration of immune cells, reversing the tumor immunosuppressive microenvironment; on the other hand, Mn 2+ It can also activate the STING pathway, promote the maturation of DC cells, further promote the proliferation and activation of T cells, increase the secretion of IFN-γ, and improve tumor killing efficiency.

[0029] (4) The preparation method of the present invention is simple, the reaction conditions are mild, and it is easy to industrialize and implement on a large scale. BRIEF DESCRIPTION OF THE DRAWINGS

[0030] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0031] Figure 1 The figures are the particle size analysis, Zeta potential, transmission electron microscope images of MLDH and MLDHI, and the valence state analysis of manganese in MLDH nanosheets; wherein A is the particle size and particle size distribution of MLDH and MLDHI, B is its Zeta potential image, C is the TEM image of MLDH, D is the TEM image of MLDHI, E is the valence state distribution image of manganese in MLDHI, F is the ultraviolet absorption spectrum of ICG, MLDH and MLDHI, and G is the element distribution image of MLDH;

[0032] Figure 2 The temperature change curves and thermal imaging representative images of different groups under laser irradiation; A is the temperature change curves of different samples under laser irradiation, and B is the thermal imaging image of each group of samples at the highest temperature under laser irradiation;

[0033] Figure 3 To determine the dissolved oxygen production of the same group;

[0034] Figure 4The ICG uptake of 4T1 cells was measured by flow cytometry after co-incubation with Free ICG and MLDHI for 4 hours with or without laser irradiation; A is a statistical bar graph of ICG uptake, and B is a representative flow cytometric graph;

[0035] Figure 5 The uptake of Free ICG and MLDHI by DC2.4 cells at 12h and 24h; A is a bar graph showing the uptake of Free ICG and MLDHI, and B is a representative flow cytometry graph;

[0036] Figure 6 The cytotoxic results of different groups of drugs co-incubated with 4T1 tumor cells under the conditions of laser irradiation or not; A is the cytotoxic results of different groups on 4T1 cells without laser irradiation, and B is the cytotoxic results of MI and MLDHI groups on 4T1 cells under laser irradiation;

[0037] Figure 7 The expression of CD86 and CD40 molecules on the surface of BMDCs was measured by flow cytometry after 4T1 tumor cells were treated with different groups and combined with laser irradiation and co-incubated with BMDCs for 24 hours; A and B are the expression of CD40 and CD86 molecules, respectively;

[0038] Figure 8 The temperature change curves and representative thermal images of the tumor site of tumor-bearing mice after intratumoral administration of PBS, MLDH, MI, LDHI and MLDHI; A is the temperature change curve, and B is the near-infrared light imaging image;

[0039] Fig. 9 The expression levels of CD40 (A), CD80 (B), and CD86 (C) molecules in mouse lymph node cells on day 12 after tumor-bearing mice were treated with PBS, MI, MLDHI, MI+L, LDHI+L, MLDH+L, and MLDHI+L intratumorally on day 0;

[0040] Fig.10 CD3+ Tgp1 expression in mouse spleen cells on day 12 after tumor-bearing mice were treated with PBS, MI, MLDHI, MI+L, LDHI+L, MLDH+L, and MLDHI+L intratumorally on day 0 + CD4 + (A) and CD3 + CD8 + (B) T cell ratio;

[0041] Fig.11CD3 expression of tumor cells in mice on day 12 after tumor-bearing mice were treated with PBS, MI, MLDHI, MI+L, LDHI+L, MLDH+L, and MLDHI+L intratumorally on day 0 + CD4 + (A) and CD3 + CD8 + (B) T cell ratio;

[0042] Fig.12 The graphs show the proportion of myeloid-derived suppressor cells (MDSCs) in tumor cells (A) and the proportion of M1 / M2 macrophages (B) in tumor-bearing mice treated with PBS, MI, MLDHI, MI+L, LDHI+L, MLDH+L, and MLDHI+L intratumorally on day 0;

[0043] Fig.13 These are the tumor growth curves, survival curves and weight gain curves of tumor-bearing mice after intratumoral administration of PBS, MI, MLDHI, MI+L, LDHI+L, MLDH+L and MLDHI+L on day 0. A is the mouse tumor volume change curve, B is the survival curve, and C is the weight gain curve. DETAILED DESCRIPTION

[0044] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.

[0045] It should be understood that the terms described in the present invention are only for describing a particular embodiment and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that each intermediate value between the upper and lower limits of the scope is also specifically disclosed. The intermediate value in any stated value or stated range, and each smaller range between any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.

[0046] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.

[0047] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments of the present invention description without departing from the scope or spirit of the present invention. Other embodiments derived from the present invention description will be apparent to those skilled in the art. The present invention description and examples are exemplary only.

[0048] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.

[0049] Example 1

[0050] A method for preparing manganese-doped layered double hydroxide drug-loaded nanoparticles, the preparation method is as follows:

[0051] (a) 5 mL of anhydrous MgCl2 solution and 5 mL of AlCl3·6H2O solution were fully mixed, and the mixed solution was quickly added into 40 mL of NaOH solution (i.e., the prepared mixed solution was immediately poured into the NaOH solution), and stirred vigorously for 10 min to obtain a mixed solution; wherein the concentration ratio of the anhydrous MgCl2 solution, AlCl3·6H2O and NaOH solution was 1 M: 0.5 M: 0.5 M;

[0052] (b) centrifuging the mixed solution and collecting the precipitate, washing the precipitate twice with deionized water to obtain a precipitate; wherein the centrifugation condition parameter is 4300g for 10 min;

[0053] (c) resuspending the above precipitate in 40 mL of deionized water, and centrifuging after hydrothermal treatment to obtain LDH precipitate; wherein the temperature of the hydrothermal reaction is 100° C., the time is 4 h; and the condition parameters of the centrifugation are centrifugation at 12000 g for 10 min;

[0054] (d) resuspending the LDH precipitate obtained after the above centrifugation with 50 mL of MnCl2 solution, vigorously stirring and centrifuging at room temperature to obtain a centrifugal precipitate; wherein the concentration of the MnCl2 solution is 10 mM; and the centrifugation condition parameters are centrifugation at 12000 g for 10 min;

[0055] (e) collecting the above centrifugal precipitate and resuspending it with 40 mL of deionized water, hydrothermally treating it and centrifuging it to obtain manganese-doped LDH (abbreviated as MLDH); wherein the temperature of the hydrothermal reaction is 100° C., the time is 4 h; and the centrifugal condition parameters are centrifugation at 12000 g for 10 min;

[0056] (f) The MLDH is freeze-dried to obtain MLDH powder, and a photosensitizer is added to the MLDH powder, and the mixture is shaken at room temperature and centrifuged to obtain the manganese-doped layered double hydroxide drug-loaded nanoparticles, wherein the photosensitizer is one of indocyanine green, IR780, and IR820. In this embodiment, indocyanine green is used as the photosensitizer; the mass ratio of the photosensitizer to the MLDH powder is 0.05 mg:1 mg; the shaking speed is 1000 rpm, and the shaking time is 30 min; and the centrifugal condition parameters are 12000 g for 10 min.

[0057] Example 2

[0058] A preparation method of manganese-doped layered double hydroxide drug-loaded nanoparticles is as follows:

[0059] (a) 5 mL of anhydrous MgCl2 solution and 5 mL of AlCl3·6H2O solution were fully mixed, and the mixed solution was quickly added to 40 mL of NaOH solution and vigorously stirred for 10 min to obtain a mixture; wherein the concentration ratio of the anhydrous MgCl2 solution, AlCl3·6H2O and NaOH solution was 1 M: 1 M: 0.5 M;

[0060] (b) centrifuging the mixed solution and collecting the precipitate, washing the precipitate twice with deionized water to obtain a precipitate; wherein the centrifugation condition parameter is 5000g for 10 min;

[0061] (c) resuspending the above precipitate in 40 mL of deionized water, and centrifuging after hydrothermal treatment to obtain LDH precipitate; wherein the temperature of the hydrothermal reaction is 90° C., the time is 4 h, and the condition parameters of the centrifugation are 12000 g for 10 min;

[0062] (d) The LDH precipitate obtained after the above centrifugation was resuspended in 50 mL of MnCl2 solution, vigorously stirred and centrifuged at room temperature to obtain a centrifugal precipitate; wherein the concentration of the MnCl2 solution was 20 mM; and the centrifugation condition parameters were 12000 g for 10 min;

[0063] (e) collecting the above centrifugal precipitate and resuspending it with 40 mL of deionized water, hydrothermally treating it and centrifuging it to obtain manganese-doped LDH (abbreviated as MLDH); wherein the temperature of the hydrothermal reaction is 90° C., the time is 4 h, and the centrifugal condition parameters are centrifugation at 12000 g for 10 min;

[0064] (f) The MLDH is freeze-dried to obtain MLDH powder, and a photosensitizer is added to the freeze-dried powder, and the mixture is shaken and centrifuged at room temperature to obtain the manganese-doped layered double hydroxide drug-loaded nanoparticles, wherein the photosensitizer is one of indocyanine green, IR780, and IR820. In this embodiment, indocyanine green is used as the photosensitizer; the mass ratio of the photosensitizer to the MLDH powder is 0.1 mg:1 mg; the shaking speed is 1000 rpm, and the shaking time is 30 min; and the centrifugal condition parameters are 12000 g for 10 min.

[0065] Example 3

[0066] A method for preparing manganese-doped layered double hydroxide drug-loaded nanoparticles, the preparation method is as follows:

[0067] (a) 5 mL of anhydrous MgCl2 solution and 5 mL of AlCl3·6H2O solution were fully mixed, and the mixed solution was quickly added to 40 mL of NaOH solution and vigorously stirred for 10 min to obtain a mixture; wherein the concentration ratio of the anhydrous MgCl2 solution, AlCl3·6H2O and NaOH solution was 1 M:0.5 M:1 M;

[0068] (b) centrifuging the mixed solution and collecting the precipitate, washing the precipitate twice with deionized water to obtain a precipitate; wherein the centrifugation condition parameter is 4500g for 10 min;

[0069] (c) resuspending the above precipitate in 40 mL of deionized water, and centrifuging after hydrothermal treatment to obtain LDH precipitate; wherein the temperature of the hydrothermal reaction is 120° C., the time is 4 h; and the condition parameters of the centrifugation are centrifugation at 15000 g for 10 min;

[0070] (d) The LDH precipitate obtained after the above centrifugation was resuspended with 50 mL of MnCl2 solution, vigorously stirred and centrifuged at room temperature to obtain a centrifugal precipitate; wherein the concentration of the MnCl2 solution was 50 mM; and the centrifugal condition parameters were centrifugation at 15000 g for 10 min; (e) The above centrifugal precipitate was collected and resuspended with 40 mL of deionized water, hydrothermally treated and centrifuged to obtain manganese-doped LDH (abbreviated as MLDH); wherein the temperature of the hydrothermal reaction was 120° C., the time was 4 h; and the centrifugal condition parameters were centrifugation at 15000 g for 10 min;

[0071] (f) The MLDH is freeze-dried to obtain MLDH powder, and a photosensitizer is added to the freeze-dried powder, and the mixture is shaken and centrifuged at room temperature to obtain the manganese-doped layered double hydroxide drug-loaded nanoparticles, wherein the photosensitizer is one of indocyanine green, IR780, and IR820. In this embodiment, indocyanine green is used as the photosensitizer; the mass ratio of the photosensitizer to the MLDH powder is 0.08 mg:1 mg; the shaking speed is 1000 rpm, and the shaking time is 30 min; and the centrifugal condition parameters are 15000 g for 10 min.

[0072] Example 4

[0073] A method for preparing manganese-doped layered double hydroxide drug-loaded nanoparticles, the preparation method is as follows:

[0074] (a) 5 mL of anhydrous MgCl2 solution and 5 mL of AlCl3·6H2O solution were fully mixed, and the mixed solution was quickly added to 40 mL of NaOH solution and vigorously stirred for 10 min to obtain a mixture; wherein the concentration ratio of the anhydrous MgCl2 solution, AlCl3·6H2O and NaOH solution was 1.4 M: 0.6 M: 0.45 M;

[0075] (b) centrifuging the mixed solution and collecting the precipitate, washing the precipitate twice with deionized water to obtain a precipitate; wherein the centrifugation condition parameter is 4300g for 10 min;

[0076] (c) resuspending the above precipitate in 40 mL of deionized water, and centrifuging after hydrothermal treatment to obtain LDH precipitate; wherein the temperature of the hydrothermal reaction is 100° C., the time is 4 h; and the condition parameters of the centrifugation are centrifugation at 12000 g for 10 min;

[0077] (d) The LDH precipitate obtained after the above centrifugation was resuspended in 50 mL of MnCl2 solution, vigorously stirred and centrifuged at room temperature to obtain a centrifugal precipitate; wherein the concentration of the MnCl2 solution was 30 mM; and the centrifugation condition parameters were centrifugation at 12000 g for 10 min;

[0078] (e) collecting the above centrifugal precipitate and resuspending it with 40 mL of deionized water, hydrothermally treating it and centrifuging it to obtain manganese-doped LDH (abbreviated as MLDH); wherein the temperature of the hydrothermal reaction is 100° C. and the time is 4 h; and the centrifugal condition parameters are centrifugation at 12000 g for 10 min.

[0079] (f) freeze-drying the MLDH to obtain MLDH powder, adding photosensitizer indocyanine green (ICG) to the freeze-dried powder, oscillating and centrifuging at room temperature to obtain the manganese-doped layered double hydroxide drug-loaded nanoparticles, wherein the mass ratio of photosensitizer indocyanine green to MLDH powder is 0.053 mg:1 mg; the oscillation speed is 1000 rpm, the oscillation time is 30 min; and the centrifugal condition parameters are centrifugation at 12000 g for 10 min.

[0080] Comparative Example 1

[0081] The preparation method of LDH is as follows:

[0082] (a) 5 mL of anhydrous MgCl2 solution and 5 mL of AlCl3·6H2O solution were fully mixed, and the mixed solution was quickly added to 40 mL of NaOH solution and vigorously stirred for 10 min to obtain a mixture; wherein the concentration ratio of the anhydrous MgCl2 solution, AlCl3·6H2O and NaOH solution was 1.4 M: 0.6 M: 0.45 M;

[0083] (b) centrifuging the mixed solution and collecting the precipitate, washing the precipitate twice with deionized water to obtain a precipitate; wherein the centrifugation condition parameter is 4300g for 10 min;

[0084] (c) resuspending the above precipitate in 40 mL of deionized water, performing hydrothermal treatment and centrifuging to obtain LDH; wherein the temperature of the hydrothermal reaction is 100° C., the time is 4 h, and the condition parameters of the centrifugation are 12000 g for 10 min.

[0085] Comparative Example 2

[0086] The preparation method of MLDH is as follows:

[0087] (a) 5 mL of anhydrous MgCl2 solution and 5 mL of AlCl3·6H2O solution were fully mixed, and the mixed solution was quickly added to 40 mL of NaOH solution and vigorously stirred for 10 min to obtain a mixture; wherein the concentration ratio of the anhydrous MgCl2 solution, AlCl3·6H2O and NaOH solution was 1.4 M: 0.6 M: 0.45 M;

[0088] (b) centrifuging the mixed solution and collecting the precipitate, washing the precipitate twice with deionized water to obtain a precipitate; wherein the centrifugation condition parameter is 4300g for 10 min;

[0089] (c) resuspending the above precipitate in 40 mL of deionized water, and centrifuging after hydrothermal treatment to obtain LDH precipitate; wherein the temperature of the hydrothermal reaction is 100° C., the time is 4 h; and the condition parameters of the centrifugation are centrifugation at 12000 g for 10 min;

[0090] (d) The LDH precipitate obtained after the above centrifugation was resuspended in 50 mL of MnCl2 solution, vigorously stirred and centrifuged at room temperature to obtain a centrifugal precipitate; wherein the concentration of the MnCl2 solution was 30 mM; and the centrifugation condition parameters were centrifugation at 12000 g for 10 min;

[0091] (e) collecting the above centrifugal precipitate and resuspending it with 40 mL of deionized water, hydrothermally treating it and centrifuging it to obtain manganese-doped LDH (abbreviated as MLDH); wherein the temperature of the hydrothermal reaction is 100° C. and the time is 4 h; and the centrifugal condition parameters are centrifugation at 12000 g for 10 min.

[0092] Comparative Example 3

[0093] The preparation method of LDHI is as follows:

[0094] (a) 5 mL of anhydrous MgCl2 solution and 5 mL of AlCl3·6H2O solution were fully mixed, and the mixed solution was quickly added to 40 mL of NaOH solution and vigorously stirred for 10 min to obtain a mixture; wherein the concentration ratio of the anhydrous MgCl2 solution, AlCl3·6H2O and NaOH solution was 1.4 M: 0.6 M: 0.45 M;

[0095] (b) centrifuging the mixed solution and collecting the precipitate, washing the precipitate twice with deionized water to obtain a precipitate; wherein the centrifugation condition parameter is 4300g for 10 min;

[0096] (c) resuspending the above precipitate in 40 mL of deionized water, and centrifuging after hydrothermal treatment to obtain LDH precipitate; wherein the temperature of the hydrothermal reaction is 100° C., the time is 4 h; and the condition parameters of the centrifugation are centrifugation at 12000 g for 10 min;

[0097] (d) freeze-drying the LDH precipitate to obtain MLDH powder, adding the photosensitizer indocyanine green to the freeze-dried powder, oscillating at room temperature and centrifuging to obtain the manganese-doped layered double hydroxide drug-loaded nanoparticles, wherein the mass ratio of the photosensitizer indocyanine green to the MLDH powder is 0.053 mg:1 mg; the oscillation speed is 1000 rpm, the oscillation time is 30 min; and the centrifugal condition parameters are centrifugation at 12000 g for 10 min.

[0098] Comparative Example 4

[0099] The preparation method of MI is as follows:

[0100] The MI was obtained by mixing equal volumes of 40 μg / mL MnO2 and 20 μg / mL MnCl2 solutions.

[0101] Experimental Example 1

[0102] The MLDH and MLDHI prepared in Example 4 were subjected to zeta potential measurement, particle size analysis, and transmission electron microscopy observation.

[0103] The results are as follows Figure 1 As shown, in Figure 1 In the figure, A is the particle size and particle size distribution of MLDH and MLDHI, B is its Zeta potential diagram. After MLDH was modified with ICG on the surface, the potential of MLDH dropped from 53.3mV to 49.2mV, which indicates the successful modification of ICG and its good stability in solution; C and D are TEM images of MLDH and MLDHI, respectively, indicating that both MLDH and MLDHI have small particle size, uniform distribution, layered and hexagonal structure, and the loading of photosensitizer ICG will not change the structure of MLDH; F is ICG, UV absorption spectra of MLDH and MLDHI. The characteristic peak of ICG appears in the UV absorption spectrum of MLDHI, indicating the successful loading of ICG. G is the element distribution image of MLDHI. It can be observed that manganese and sulfur (characteristic elements of ICG) are evenly distributed in the MLDHI nanosheets, which indicates the successful doping of manganese and the successful loading of ICG on the MLDH nanosheets. E is the valence state analysis of manganese in MLDH, in which the peaks of 641.1eV and 653.1eV are attributed to Mn 2p, respectively. 3 / 2 and Mn 2p 1 / 2 , and its spin energy separation was calculated to be 12eV, indicating that the main valence state of Mn in MLDH nanosheets is Mn(IV), which also gives MLDH nanosheets the ability to catalyze H2O2 to produce oxygen, thereby alleviating the hypoxic microenvironment of tumors. In addition, the amount of manganese doped in LDH nanosheets was quantitatively analyzed by inductively coupled plasma spectroscopy / mass spectrometry, and the results showed that each mg of LDH nanosheets contained 79.14μg of manganese.

[0104] Experimental Example 2

[0105] PBS, MLDH and MLDHI prepared in Example 4, LDH prepared in Comparative Example 1, LDHI prepared in Comparative Example 3, MI (free ICG, MnO2, MnCl2) prepared in Comparative Example 4, and I (photosensitizer, i.e., free ICG) (equivalent ICG concentration of 20 μg / mL, LDH concentration of 377 μg / mL) were heated at 1.0 W / cm 2 The laser was irradiated with a power intensity of 808 for 5 min, the temperature changes were recorded by thermal imaging, and representative thermal images were taken.

[0106] The results are as follows Figure 2 As shown, in Figure 2In the figure, A is the temperature change curve of different samples under laser irradiation, and B is the thermal imaging of each group of samples at the highest temperature under laser irradiation. The results show that the temperature of the MI group is higher than that of the I group, indicating that the doping of the metal element manganese improves the photothermal heating effect; while the temperature of the MLDHI group is higher than that of the MI group, indicating that the doped manganese amplifies the photothermal effect of the photosensitizer ICG to a certain extent, and because ICG is loaded in the nanostructure of MLDH, its stability is further improved, and it has good photothermal performance and temperature stability.

[0107] Experimental Example 3

[0108] 50 μL of MLDH and MLDHI prepared in Example 4, LDH prepared in Comparative Example 1, MnO2 (MnO2 concentration is 20 μg / mL) and PBS were added to the H2O2 solution to make the final concentration of H2O2 in the mixed solution be 100 μM. The mixture was incubated at room temperature for 10 min, and the dissolved oxygen content in the solution per minute was measured using a dissolved oxygen meter.

[0109] The results are as follows Figure 3 As shown, MLDH and MLDHI can continuously and stably produce a higher content of dissolved oxygen. This is because the presence of tetravalent manganese ions in MLDH and MLDHI can catalyze H2O2 to produce O2, which has a good oxygen production effect.

[0110] Experimental Example 4

[0111] ICG and MLDHI prepared in Example 4 were irradiated with or without laser (1 W / cm 2 , 5 min) and incubated with 4T1 tumor cells for 4 h, and the uptake of ICG by 4T1 cells was detected by flow cytometry.

[0112] The results are as follows Figure 4 As shown, the results indicate that compared with the ICG group, MLDHI treatment can significantly promote the uptake of ICG by 4T1 cells, because the positively charged MLDHI can more easily enter the negatively charged tumor cells through electrostatic action; laser irradiation (ICG+L, MLDHI+L) can further promote the uptake of ICG by 4T1 cells, because laser irradiation can increase the permeability and fluidity of the cell membrane, thereby increasing the amount of ICG uptake.

[0113] Experimental Example 5

[0114] ICG and the MLDHI prepared in Example 4 were co-incubated with DC2.4 cells for 12 and 24 hours, respectively, and the uptake of ICG by DC2.4 cells was detected by flow cytometry.

[0115] The results are as follows Figure 5As shown, the results showed that the MLDHI group showed stronger ICG uptake than the ICG group, which was due to the fact that the positively charged MLDHI was more likely to interact with cells, and the uptake of ICG was further improved with the extension of incubation time.

[0116] Experimental Example 6

[0117] PBS, MLDHI prepared in Example 4, LDH prepared in Comparative Example 1, MLDH prepared in Comparative Example 3, and MI prepared in Comparative Example 4 were co-incubated with 4T1 tumor cells for 24 h, and the killing effect of different groups on 4T1 cells was detected using a CCK-8 kit. At the same time, MI, MLDHI prepared in Example 4, and 4T1 tumor cells were irradiated with laser (1 W / cm 2 , 5 min) for 24 h, and the CCK-8 kit was used to detect the killing effect of different groups on 4T1 cells.

[0118] The results are as follows Figure 6 As shown, in Figure 6 In the figure, A shows the cytotoxicity of different groups to 4T1 cells without laser irradiation. The results show that MLDHI, MLDH and LDH all showed negligible cytotoxicity without laser irradiation, while the MI group showed obvious cytotoxicity when the manganese ion concentration was higher than 30 μg / mL. This is because Mn 2+ It can catalyze hydrogen peroxide to produce cytotoxic ·OH, thereby killing cells; B is the cytotoxic results of MI and MLDHI groups on 4T1 cells under laser irradiation. The results show that under laser irradiation, due to the photothermal effect produced by ICG, the killing effect of MI on 4T1 cells is further enhanced, and the MLDHI group also shows improved cytotoxicity, and this killing effect shows obvious ICG concentration dependence. When the ICG concentration is higher than 20μg / mL, both MI and MLDHI groups show a significant inhibitory effect on the survival rate of 4T1 cells, and the MLDHI group has the strongest inhibitory effect. This may be because compared with MI, MLDHI can be taken up by cells faster and more effectively, and can further generate more heat under laser irradiation to kill tumor cells.

[0119] Experimental Example 7

[0120] 4T1 cells were incubated with PBS, MLDHI prepared in Example 4, MLDH prepared in Comparative Example 1, LDHI prepared in Comparative Example 3, and MI prepared in Comparative Example 4 for 2 h and then irradiated with laser (1 W / cm 2 , 5min) and then continued to incubate for 2h, then BMDCs were collected and co-incubated with 4T1 cells treated with the above different groups for 24h, and flow cytometry was used to evaluate the maturation-promoting effects of different groups on BMDCs.

[0121] The results are as follows Figure 7 As shown, in Figure 7 In the figure, A and B are the expression of CD40 and CD86 molecules, respectively. The results show that under laser irradiation, the 4T1 tumor cell group co-incubated with the MLDHI group can induce the highest level of CD40 and CD86 molecule expression. This is because MLDHI has the strongest tumor killing effect under laser irradiation and can produce a very high level of dsDNA. In addition, the Mn doped by MLDHI itself 2+ , which can activate the STING pathway of BMDCs cells at the maximum level, thereby promoting the maturation and activation of BMDCs cells.

[0122] Experimental Example 8

[0123] BALB / C mice aged 6-8 weeks were inoculated on the right back with 1 × 10 6 4T1 cells were used to construct an orthotopic tumor model. After the orthotopic tumor grew to 75 mm 3 At the time of administration, the mice were randomly divided into 7 groups, 8 mice in each group, and 50 μL of different groups of drugs (ICG dose was 1.25 mg / kg body weight; Mn dose was 2.5 mg / kg body weight) were injected intratumorally. The groups were as follows: PBS, MI, MLDHI, MI+L, LDHI+L, MLDH+L, MLDHI+L. After administration, the mice were irradiated with near-infrared 808 laser for 5 min (0.35 W / cm 2 ) and draw the temperature change curve of the tumor site.

[0124] The temperature change curve of the mouse tumor site is as follows Figure 8 As shown in A (temperature change curve) and B (near-infrared light imaging), the temperature of the PBS group can only rise to 39°C at most after laser irradiation; the temperature of the MLDH group can rise to 43°C, which can be attributed to the weak photothermal effect of metallic manganese. The temperature of the LDHI group can rise to 47°C after laser irradiation, the temperature of the MI group can rise to 52°C after laser irradiation, and the temperature of the MLDHI group can rise rapidly and stabilize at 53°C after laser irradiation. This is because the atomically dispersed manganese in the nanosheets greatly amplifies the photothermal heating effect and shows the potential to effectively kill tumor cells.

[0125] Experimental Example 9

[0126] BALB / C mice aged 6-8 weeks were inoculated on the right back with 1 × 10 6 4T1 cells were used to construct an orthotopic tumor model. After the orthotopic tumor grew to 75 mm 3At the same time, the mice were randomly divided into 7 groups, 3 mice in each group, and 50 μL of different groups of drugs (ICG dose was 1.25 mg / kg; Mn dose was 2.5 mg / kg) were injected intratumorally. The groups were divided into the following groups: PBS, MI, MLDHI, MI+L, LDHI+L, MLDH+L, MLDHI+L. After drug administration, the laser group was irradiated with near-infrared 808 laser for 5 min (0.35 W / cm 2 ), which is day 0. On day 12, the mice were killed, and the inguinal lymph nodes, spleens and tumors of the mice in each group were collected, ground into single-cell suspensions, labeled with different antibodies, and detected by flow cytometry.

[0127] CD40, CD80, and CD86 are co-stimulatory molecules widely expressed on the surface of DC cells, and their expression is significantly upregulated when DC cells mature. Fig. 9 The CD40, CD80 and CD86 molecular expression levels and representative cell population distribution diagram of lymph node cells of tumor-bearing mice on day 12 after intratumoral administration of PBS, MI, MLDHI, MI+L, LDHI+L, MLDH+L, and MLDHI+L on day 0; A, B, and C are the expression levels of CD40, CD80, and CD86 molecules, respectively. Fig. 9 As shown, manganese-doped layered double hydroxide drug-loaded nanoparticles MLDHI combined with laser irradiation (MLDHI+L) can promote the maturation of DC cells in lymph nodes to the greatest extent and upregulate the expression of CD40, CD80, and CD86 molecules. This is because MLDHI can produce the strongest light effect under laser irradiation, producing sufficient tumor-associated antigens to activate immunity; in addition, manganese doped in the form of atomic dispersion in MLDHI can effectively activate the STING pathway and further enhance the immune response.

[0128] Helper T cells (CD4 + T cells) and effector T cells (CD8 + T cells) are the two main subtypes of T cells and play a vital role in tumor immune response. Fig.10 CD3+ Tgp1 expression in mouse spleen cells on day 12 after tumor-bearing mice were treated with PBS, MI, MLDHI, MI+L, LDHI+L, MLDH+L, and MLDHI+L intratumorally on day 0 + CD4 + and CD3 + CD8 + T cell ratio and cell population distribution diagram; A and B are CD3 + CD4 + and CD3 + CD8 +The results showed that the manganese-doped layered double hydroxide drug-loaded nanoparticles MLDHI combined with laser irradiation (MLDHI+L) had the highest CD3 + CD4 + and CD3 + CD8 + This shows that MLDHI combined with laser irradiation can effectively activate systemic immune response.

[0129] Fig.11 CD3 expression of tumor cells in mice on day 12 after tumor-bearing mice were treated with PBS, MI, MLDHI, MI+L, LDHI+L, MLDH+L, and MLDHI+L intratumorally on day 0 + CD4 + 、CD3 + CD8 + T cell ratio and cell population distribution diagram; A and B are CD3 + CD4 + and CD3 + CD8 + The results show that manganese-doped layered double hydroxide drug-loaded nanoparticles MLDHI combined with laser irradiation (MLDHI+L) can kill tumor cells to the greatest extent, activate the STING pathway, effectively activate the body's immunity, and thus upregulate tumor-infiltrating CD3 + CD4 + and CD3 + CD8 + The proportion of T cells.

[0130] Myeloid-derived suppressor cells (MDSCs) and M2 macrophages are two major types of immunosuppressive cells that have the ability to significantly inhibit immune cell responses. The weakly acidic, hypoxic tumor microenvironment promotes the proliferation of MDSCs cells and the differentiation of tumor-associated macrophages into M2. Remodeling the tumor microenvironment can reduce the proportion of MDSCs and M2 macrophages and alleviate the immunosuppressive state. Fig.12 The figure shows the proportion of MDSCs cells and the proportion of M1 / M2 macrophages in tumor cells of tumor-bearing mice on day 12 after intratumoral administration of PBS, MI, MLDHI, MI+L, LDHI+L, MLDH+L, and MLDHI+L on day 0; A and B are the proportion of MDSCs cells and the proportion of M1 / M2 macrophages, respectively. Fig.12As shown, manganese-doped layered double hydroxide drug-loaded nanoparticles MLDHI combined with laser irradiation (MLDHI+L) can significantly reduce the proportion of MDSCs cells and significantly promote the M1 transformation of tumor-associated macrophages. This is mainly because MLDHI can neutralize the acidic tumor microenvironment and effectively relieve the hypoxic state, thereby reshaping the inhibitory tumor immune microenvironment. Combined with laser irradiation, it can activate immunity to the greatest extent.

[0131] Experimental Example 10

[0132] BALB / C mice aged 6-8 weeks were inoculated on the right back with 1 × 10 6 4T1 cells were used to construct an orthotopic tumor model. After the orthotopic tumor grew to 75 mm 3 At the same time, the mice were randomly divided into 7 groups, 8 mice in each group, and 50 μL of different drugs (ICG dose was 1.25 mg / kg body weight; Mn dose was 2.5 mg / kg body weight) were injected intratumorally. The groups were divided into the following groups: PBS, MI, MLDHI, MI+L, LDHI+L, MLDH+L, MLDHI+L. After drug administration, the laser group was irradiated with near-infrared 808 laser for 5 min (0.35 W / cm 2 ), the weight and tumor volume of mice were recorded every other day since the start of drug administration, and the tumor growth curve and weight change curve were drawn (V = 0.52 × L × W 2 ); when the tumor volume exceeds 1500mm 3 The mice were killed and the survival rate curve was drawn.

[0133] Draw a curve like Fig.13 As shown, in Fig.13 In the figure, A is the mouse tumor volume change curve, B is the survival curve, and C is the weight gain curve. Fig.13 It can be seen that the tumor volume of mice in the PBS group increased rapidly, and the average tumor volume was close to 1200mm 20 days after tumor inoculation. 3; The free drug MI group and the simple ICG-loaded manganese-doped layered double hydroxide nanoparticles MLDHI group had almost no inhibitory effect on tumor growth. This is because both the preparations MI and MLDHI showed only a weak killing effect on tumor cells without the application of laser. Manganese-doped layered double hydroxide nanoparticles MLDH combined with laser irradiation showed a slight tumor inhibition effect, which was due to the weak photothermal effect on tumor cells. ICG-loaded layered double hydroxide nanoparticles LDHI combined with laser irradiation can inhibit tumor growth to a large extent. This is because the temperature of the tumor treated with LDHI under laser irradiation can reach 47°C, and the mediated low-temperature photothermal can achieve damage to tumor cell proteins. The tumor inhibition effect of the free drug MI group combined with laser irradiation is second only to the MLDHI+L group. This is because the MI group can rise to 52°C under laser irradiation and has a good ability to thermally ablate tumor cells. MLDHI combined with laser irradiation significantly inhibited tumor growth, and achieved complete tumor ablation in 6 of the 8 mice in the experimental group, with a cure rate of 75%. This is because while effectively photothermally ablating tumor cells, the doped manganese can also effectively alleviate the hypoxic environment in the tumor site, enhance the photodynamic effect, and the nanoparticles can neutralize the acidic tumor microenvironment, relieve the inhibitory effect of the acidic microenvironment on immune cells, activate the immune system, and trigger a powerful body immunity to kill tumor cells. Fig.13 As shown in Figure B, the survival rate of 4T1 tumor-bearing mice in the MLDHI+L group was significantly improved compared with the other groups (all survived within 38 days); Fig.13 As shown in C, each drug-treated group did not cause a significant decrease in mouse body weight, indicating that the drug system did not have obvious organ toxicity.

[0134] In summary, the manganese-doped layered double hydroxide drug-loaded nanoparticles prepared by the preparation method provided by the present invention combined with near-infrared laser irradiation can effectively kill tumors, providing a new direction for the treatment of tumors.

[0135] The embodiments described above are only descriptions of the preferred modes of the present invention, and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope determined by the claims of the present invention.

Claims

1. A method for preparing manganese-doped layered double hydroxide drug-loaded nanoparticles, characterized in that: The following steps are involved: (1) After fully mixing the MgCl2 solution and the AlCl3 solution, the mixture is added to the NaOH solution to obtain a mixed solution; (2) centrifuging the mixed solution and collecting the precipitate to obtain a precipitate; (3) resuspending the precipitate in deionized water, and sequentially performing hydrothermal treatment and centrifugation to obtain LDH precipitate; (4) resuspending the LDH precipitate with a MnCl2 solution, stirring and centrifuging in sequence to obtain a centrifugal precipitate; (5) resuspending the centrifugal precipitate with deionized water, and then performing hydrothermal treatment and centrifugation in sequence to obtain a manganese-doped LDH precipitate; (6) After freeze-drying the manganese-doped LDH precipitate, mixing it with a photosensitizer, and performing shaking treatment and centrifugation to obtain the manganese-doped layered double hydroxide drug-loaded nanoparticles.

2. The preparation method according to claim 1, characterized in that: In step (1), the MgCl2 solution is an anhydrous MgCl2 solution; the AlCl3 solution is an AlCl3·6H2O solution; The concentration ratio of the MgCl2 solution, the AlCl3 solution and the NaOH solution is (1-1.4)M:(0.5-1)M:(0.45-1)M; The volume ratio of the MgCl2 solution, the AlCl3 solution and the NaOH solution is 5:5:

40.

3. The preparation method according to claim 1, characterized in that: In step (2), the centrifugal treatment condition parameters are (4300-5000) g centrifugation for 10 min.

4. The preparation method according to claim 1, characterized in that: In step (3), the temperature of the hydrothermal treatment is (90-120)°C and the time is 4-6 hours; the centrifugal condition parameters are (12000-15000) g for 10 minutes.

5. The preparation method according to claim 1, characterized in that: In step (5), the temperature of the hydrothermal treatment is (90-120)°C and the time is 4-6 hours; the centrifugal condition parameters are (12000-15000) g for 10 minutes.

6. The preparation method according to claim 1, characterized in that: In step (6), the mass ratio of the lyophilized powder obtained after lyophilization to the photosensitizer is (0.05-0.1):

1.

7. The preparation method according to claim 1 or 6, characterized in that: The photosensitizer is one of indocyanine green, IR780 and IR820.

8. Manganese-doped layered double hydroxide drug-loaded nanoparticles prepared by the preparation method according to any one of claims 1 to 7.

9. Use of the manganese-doped layered double hydroxide drug-loaded nanoparticles according to claim 8 in the preparation of anti-tumor drugs.

10. An anti-tumor system, characterized in that: The anti-tumor system comprises: a) the manganese-doped layered double hydroxide drug-loaded nanoparticles according to claim 8; and b) a light irradiation device.

Citation Information

Patent Citations

  • Layered double-hydroxide nano drug-loaded compound and preparation and application thereof

    CN110755617A

Cited By

  • Nitrogen-doped manganese-loaded layered double hydroxide as well as preparation and application thereof

    CN119746846A

  • LDH nano composite material loaded with CD105 nano antibody as well as preparation method and application of LDH nano composite material

    CN120815191A

  • LDH nanocomposites loaded with cd105 nanobodies, methods of making and uses thereof

    CN120815191B